title: Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD).
abstract: OBJECTIVE
  (1) Evaluate the safety and efficacy of Ultra Rapid Opiate Detoxification (UROD); and (2) evaluate six month outcome data of patients choosing this method.
  
  
  METHODS
  Two center parallel group clinical trial. No grant funding.
  
  
  METHODS
  Two academic medical centers.
  
  
  METHODS
  Ninety-three men and 27 women, aged 18 to 55 years, with opiate dependency self selected to undergo detoxification.
  
  
  METHODS
  UROD followed by naltrexone maintenance and an aftercare program. UROD and aftercare costs were the responsibility of the patients and/or their significant others.
  
  
  METHODS
  (1) Completion of UROD as determined by a non reactive response to a naloxone challenge test under anesthesia and non reactive response to naltrexone administration before discharge. (2) Patient outcome as determined at six month follow up of UROD patients' self reported relapse free status confirmed by urine drug screen, significant other reports, and/or therapist reports.
  
  
  RESULTS
  One hundred percent successful detoxification with UROD with low morbidity and no mortality. Relapse data were available for 111/123 procedures performed (90%), with 61/111 patients (55%) with reported relapse free status at the six month follow up interval.
  
  
  CONCLUSIONS
  For individuals who are addicted to opioids, the Ultra Rapid Opiate Detoxification method appears to be a viable treatment option.
authors.affiliation: Mount Sinai Medical Center, University of Miami School of Medicine, Miami Beach, FL 33140, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Albanese
authors.forename: C
authors.initials: C
authors.lastname: Gevirtz
authors.forename: B
authors.initials: B
authors.lastname: Oppenheim
authors.forename: J M
authors.initials: JM
authors.lastname: Field
authors.forename: I
authors.initials: I
authors.lastname: Abels
authors.forename: J C
authors.initials: JC
authors.lastname: Eustace
mesh_terms: D000293:Adolescent; D000328:Adult; D000359:Aftercare; D000768:Anesthesia, General; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000009:adverse effects / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D010043:Outcome and Process Assessment, Health Care; D012008:Recurrence; D019233:Retreatment; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control
chemical_list: D009292:Narcotic Antagonists; D009271:Naltrexone